Dwarkesh Pharmaceuticals Pvt. Ltd.

Cambridge Major Laboratories, Inc. and AAIPharma Services Corp. (AAI|CML) have merged to form a world-class supplier of comprehensive pharmaceutical development and manufacturing services. With over 800 employees operating out of seven sites in the US and Europe, our combined capabilities include API development and manufacturing, solid state chemistry, formulation and analytical development, material testing, finished dosage form manufacturing (solid dose and parenteral), packaging, and stability services.

AAI|CML offers comprehensive services to expedite drug products through the full range of development – from early phase studies to full-scale (commercial) production of APIs and finished dosage forms. In addition to our development capabilities, our network of regional analytical testing laboratories located in St. Louis, MO; Edison, NJ; Durham, NC; and Wilmington, NC provides industry-leading turn-around-times.

CML has five centers of excellence: process chemistry, solid state chemistry, API manufacturing, analytical services, and quality assurance.

To learn more, visit www.aaipharma.com and www.c-mlabs.com.

Compounding Solutions LLC is a global leader in the manufacturing of custom medical polymer compounds, color concentrates, and additive concentrates for extrusion and injection molding to be used in Class I, II, and III medical devices. Our custom formulation capabilities include radiopaque, pre-colored, heat & UV stabilized, and low friction. Our product lines include ReZilok Rx tie layer resins, ReZilient TPEs, Mobilize low-friction and radiopaque fillers.

Our sophisticated on-site laboratory and development equipment enables us to offer the opportunity for our customers to team up with our product engineers and material specialists to develop and manufacture your exact material. Our facility is ISO 13485:2016 compliant.

Design Plus Health & Beauty is the UK specialist, one stop sachet manufacturer from development, testing, design, manufacture and fulfilment. We promote innovation from concept creation to delivery of market ready products. With all of our service centres under one roof we’re the perfect partner to help your health and beauty brands grow.

Established in 2000, Design Plus Health & Beauty has grown from a privately-owned company, to be part of DCC Health & Beauty Solutions - one of Europe’s leading outsourced service providers to the health and beauty sector.

Design Plus work with a range of clients including internationally recognised cosmetic brands to specialist medical suppliers, leading the way in full-service manufacture, formulation development and bespoke filling and packaging.

The company’s product and service range include;

• Conventional and shaped sachets filled with liquids, powders, wipes and capsules
• Bottle & tube filling
• Product formulation
• Private Label

Design Plus Health and Beauty bring together a purpose-built facility, years of expertise, state of the art technology and a network of industry specialists. We’re proud to have a dedicated team of 94 employees at our 34,000 sq. ft Morecambe site complete with account management, laboratory, quality control, finance, marketing, manufacturing, production and warehouse departments.

We’re an expert and personable team aligned in 4 common core values for what we do; partnership, integrity, excellence and safety.

Design Plus is part of Laleham Health & Beauty. A subsidiary of DCC Plc. We’re proud to be part of DCC plc; an ambitious and entrepreneurial FTSE 100 company. DCC plc employ approximately 11,500 people across four divisions and operate in 17 countries. To find out more visit www.dcc.ie.

Who are we?
Efarmes is a generic pharmaceutical company devoted to develop and manufacture generics for third parties all over the world. Efarmes Generics Company is part of Lacer Group. Our head offices, manufacturing site with EU cGMP’s and R&D area are in Barcelona.

What we do?
Efarmes Generics Company seeks partners that want to in-license and market the generics. Our partners are both multinational and local pharmaceutical companies on the five continents. Efarmes Generics Company offers tailored-made proposals such as full development and manufacturing of generic pharmaceutical products ready to be marketed by third parties under their own brand name, co-development of generic products, and contract manufacturing.

How we do it?
Efarmes Generics Company covers all levels from formulation to finished product delivery. Efarmes Generics Company currently supplies finished dosage forms to many key players all over the world. Our manufacturing site plant produced last year 24 M units (3.240 batches) with 99,9% Quality Control Conforming.

Our Business Proposal
Our main business model is the out license and supply of generic finished dosage forms. Our dossiers are in EU CTD format and ready to file. We have some MAs available in Europe.

Dossiers ready to file:
- Rasagiline (Parkinson’s diseases)
- Alprazolam (Anxiolytic)
- Deflazacort (Corticosteroid)
- Modafinil (Narcolepsy)
- Sildenafil (Erectil Dysfunction)
- Pioglitazone (Diabetes)
- Rivastigmine (Alzheimer diseases)

Dossiers under development:
- Olmersartan + Amlodipine + Hidroclorothiazide (Hypertension). Q2 2016 Bioequivalence studies on-going.
- Tapentadol, retard tabs, (Neurophatic Pain). Dossier will be available in 2018.

Products which are subject to patent are currently not offered or made available in countries where patents are in force. No orders or deliveries prior to the expiry date of valid patents are possible.

Please, contact us on generics@efarmes.es

Elite Pharmaceuticals, Inc. develops oral sustained and controlled release products. Elite's strategy includes assisting partner companies in the life cycle management of products, to improve off-patent drug products, and developing generic versions of controlled release drug products with high barriers to entry. Elite has four ANDA products partnered with TAGI Pharma; one ANDA has launched, two ANDAs are in the process of a manufacturing site transfer and an additional ANDA is currently under review by the FDA. Elite also manufactures Lodrane D® and receives royalties for Lodrane D®, an allergy product partnered with ECR Pharmaceuticals (“ECR”), a wholly owned subsidiary of Hi-Tech Pharmacal (“Hi-Tech”). Elite’s lead pipeline products, ELI-216, a once-daily abuse resistant oxycodone, and ELI-154, a once-daily oxycodone, are novel sustained release oral formulations of opioids for the treatment of chronic pain, which address two of the limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential abuse. Elite also has partnered with Mikah Pharma to develop a new product and with Hi-Tech Pharmacal to develop an intermediate for a generic product. Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ.